Shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI – Get Free Report) were up 1.3% during trading on Friday . The stock traded as high as $0.18 and last traded at $0.16. Approximately 1,103,124 shares changed hands during trading, an increase of 5% from the average daily volume of 1,049,327 shares. The stock had previously closed at $0.16.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on CLDI shares. Robert W. Baird lowered their price objective on shares of Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating on the stock in a research report on Thursday, March 21st. HC Wainwright dropped their price target on Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st.
Get Our Latest Stock Report on Calidi Biotherapeutics
Calidi Biotherapeutics Stock Up 1.3 %
About Calidi Biotherapeutics
Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.
Further Reading
- Five stocks we like better than Calidi Biotherapeutics
- Transportation Stocks Investing
- Comprehensive Analysis of PayPal Stock
- How to Use the MarketBeat Dividend Calculator
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- What is the Dow Jones Industrial Average (DJIA)?
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Calidi Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calidi Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
